The CNS data from ongoing and recent phase 3 trials of osimertinib (ADAURA [AZD9291 vs Placebo in Patients With Stage IB-IIIA Non–Small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy],17 ASTRIS [Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC],18 and APOLLO [Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM [brain metastases] From NSCLC Patients With EGFR T790M]19) will provide additional information on effectiveness in patients with IMD. This evidence concerns the gene EGFR and non-small cell lung carcinoma.